La traducción al español está en camino; mientras tanto se muestra la versión en inglés.
Hong Kong pharma shares weaken; 金斯瑞生物科技 falls 13.72%
En breve
Hong Kong-listed pharmaceutical shares mostly weakened on Oct 7, 2026. 金斯瑞生物科技 (01548.HK) fell 13.72% and 昭衍新药 (06127.HK) fell 11.93% as of 09:49 local time, with Jiemian reporting the same figures at 10:22. Yicai reported the sector was mostly lower without listing individual moves.
Leer la noticia completa 1 min de lectura
Hong Kong-listed pharmaceutical shares mostly fell in morning trading on Oct 7, 2026, business outlets reported. As of 09:49 local time, 金斯瑞生物科技 (01548.HK) was down 13.72%, 昭衍新药 (06127.HK) down 11.93%, 维亚生物 (01873.HK) down 7.12%, and 泰格医药 (03347.HK) down 5.64%, according to CLS. Jiemian later reported the same declines as of its 10:22 publication, while Yicai reported at 09:57 that the sector was mostly weaker without listing figures. [ 1 , 2 , 3 ]
The documents did not state a reason for the declines or cite any company, regulatory or market statement as the cause. CLS and Jiemian provided the individual percentage moves, while Yicai gave only the broad sector direction. No document gave a sector-wide index move, a closing level, or an indication that trading had ended. [ 1 , 2 , 3 ]
Por qué importa
The reports point to sharp early pressure on several Hong Kong-listed biotech and clinical research companies. Because the documents give no cause, they do not establish whether the declines reflect company-specific news or broader sector sentiment.
Datos clave
- Hong Kong-listed pharmaceutical shares mostly weakened on Oct 7, 2026, according to CLS, Yicai and Jiemian. [ 1 , 2 , 3 ]
- 金斯瑞生物科技 (01548.HK) was down 13.72% as of 09:49 local time, according to CLS, and Jiemian reported the same figure at 10:22. [ 1 , 3 ]
- 昭衍新药 (06127.HK) fell 11.93%, according to CLS and Jiemian. [ 1 , 3 ]
- 维亚生物 (01873.HK) fell 7.12%, according to CLS and Jiemian. [ 1 , 3 ]
- 泰格医药 (03347.HK) fell 5.64%, according to CLS and Jiemian. [ 1 , 3 ]
- Yicai reported the sector was mostly weaker without naming individual stocks or percentage moves. [ 2 ]
Confirmado por varias fuentes
Aún sin aclarar
- What caused the declines. No document states a reason or cites any company, regulatory or market statement as the cause.
- Whether the declines continued or reversed after publication. The documents provide only snapshots at 09:49 and 10:22 local time, with no later data.
- How broad the sector decline was. The documents say most pharmaceutical stocks weakened but list only four companies and give no sector index or number of decliners.
Qué dicen los medios locales
Cronología, hora local
- CLS reported that, as of publication, 金斯瑞生物科技 (01548.HK) was down 13.72%, 昭衍新药 (06127.HK) down 11.93%, 维亚生物 (01873.HK) down 7.12%, and 泰格医药 (03347.HK) down 5.64%. [ 1 ]
- Yicai reported that Hong Kong-listed pharmaceutical shares were mostly weaker. [ 2 ]
- Jiemian reported the same four percentage declines as CLS, citing the moves as of publication. [ 3 ]